BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.17.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20210527T190000
DTEND;TZID=Africa/Nairobi:20210527T203000
DTSTAMP:20211024T153904Z
CREATED:20210530T161355Z
LAST-MODIFIED:20211024T153904Z
UID:5219-1622142000-1622147400@kesho-kenya.org
SUMMARY:HR+/HER2-Ve Advanced Breast Cancer
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Prof Alice Musibi\, Assistant Professor and Medical Oncologist\, Kenyatta National Hospital \nSponsor: Novartis \nPresenters: \n\nDr. James Mbogo\, clinical oncologist working with Dr. Vj Oncology Associates based at the Nairobi West Hospital.\n\nTreatment choice for advanced breast cancer should take into account hormone receptor and HER-2 status and germline BRCA status of the patient\, in addition to PIK3CA in HR+ and PD-L1 in TNBC patients. It’s important to consider the accessibility of targeted therapies\, previous therapies\, and their toxicities. Other important factors to consider include tumor burden\, biological age\, comorbidities\, menopausal status\, need for rapid disease/ symptom control\, socioeconomic and psychological factors\, available therapies\, and patients preference. Endocrine-based therapy is preferred for hormone receptor-positive disease in patients with visceral disease. The presence of visceral crisis as a result of severe organ dysfunction can be determined by signs and symptoms\, laboratory studies\, and rapid progression of the disease. Its presence implies important visceral compromise; a clinical indication for a more rapidly efficacious therapy\, particularly because another treatment option at progression will probably not be possible. For pre-menopausal women for whom endocrine therapy was decided\, ovarian suppression/ablation (through surgery and radiation) combined with additional endocrine-based therapy is the preferred choice. Primary and secondary endocrine resistance after endocrine therapy is associated with various mechanisms. A CDK4/6 inhibitor combined with endocrine therapy is the standard of care for patients with ER+/HER-2 negative advanced breast cancers. The body composition parameters may influence prognosis in patients receiving CDK4/6 inhibitors\, whose side-effects include bone marrow toxicities\, liver enzymes\, fatigue\, pain\, skin toxicities (rashes)\, vomiting\, and neutropenia.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column]    \n    	\n                	Webinar Recording                \n        \n    \n    [vc_column_text][vc_row][vc_column][vc_message]Dear Guest\, this content is restricted to only KESHO Members.[/vc_message][vc_row_inner][vc_column_inner width="1/3"]    	\n        Access our Membership Page        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Fill in the Membership Form        \n        [/vc_column_inner][vc_column_inner width="1/3"]    	\n        Access Membership Portal        \n        [/vc_column_inner][/vc_row_inner][/vc_column][/vc_row] \n[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][vc_column_text] \n\n\n\n\n \n\n\n[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/hr-her2-ve-advanced-breast-cancer/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2021,Webinar Recording Available
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2021/05/HRHER2-ve-Advanced-Breast-Cancer.png
END:VEVENT
END:VCALENDAR